Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market is anticipated to reach at a CAGR of 25% during the forecast period 2022-2028.

Nonalcoholic steatohepatitis is a form of liver disease that occurs in people who consume little or no alcohol. Nonalcoholic steatohepatitis (NASH) is one of the most common liver diseases, often called silent liver disease. A key characteristic of NASH is the accumulation of fat in the liver along with inflammation. Nonalcoholic steatohepatitis (NASH) is a type of NAFLD. NASH is liver inflammation and damage caused by the accumulation of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD).

Market Segments

By Therapeutics

• Ocaliva
• Elafibranor
• Cenicriviroc
• Selonsertib
• Others

By Diagnostics

• Imaging Techniques
• Diagnostic Tests
• Biopsy

Key Players

• Siemens Healthcare GmbH
• Celerion
• ZyVersa Therapeutics, Inc.
• Cisbio
• Regeneron Pharmaceuticals, Inc.
• BioPredictive
• Echosens
• Genfit
• Enterome
• NGM Biopharmaceuticals

Scope of the Report

The research study analyzes the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Report

1. What was the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.